News

Narrow-Moat Alnylam's Strong Launch of Amvuttra for ATTR-CM Drives Growth; Pipeline Makes Progress

Onpattro is the first approved RNA interference therapy. In addition to first-mover advantage, Alnylam is positioned to expand its reach in ATTR amyloidosis with next-generation Amvuttra, which is ...
Cook What You Love on MSN42m

19 Cookout-Worthy BBQ That Delivers Real Flavor Without the Long Wait and Keeps the Whole Crowd on Standby

The post 19 Cookout-Worthy BBQ That Delivers Real Flavor Without the Long Wait and Keeps the Whole Crowd on Standby appeared ...